HOOKIPA Pharma Inc (HOOK) USD0.0001

Sell:$1.79Buy:$1.85$0.01 (0.53%)

Prices delayed by at least 15 minutes
Sell:$1.79
Buy:$1.85
Change:$0.01 (0.53%)
Prices delayed by at least 15 minutes
Sell:$1.79
Buy:$1.85
Change:$0.01 (0.53%)
Prices delayed by at least 15 minutes

Company Information

About this company

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Key people

Malte Peters
Chief Executive Officer, Director
Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Roman Necina
Chief Operations Officer
Klaus Orlinger
Chief Scientific Officer
Mark Winderlich
Chief Development Officer
Julie O'Neill
Non-Executive Independent Chairman of the Board
Sean A. Cassidy
Director
David R. Kaufman
Independent Director
Timothy Reilly
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US43906K2096
  • Market cap
    $22.78m
  • Employees
    151
  • Shares in issue
    9.66m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.